(Q33447413)

26 July 2017

title

Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry (English)

1 reference

26 July 2017

Henrik Sillén

1

1 reference

26 July 2017

Melanie Cook

2

1 reference

26 July 2017

Patty Davis

3

1 reference

26 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20688583

17 June 2024

publication date

25 June 2010

1 reference

full work available at URL

26 July 2017

https://api.elsevier.com/content/article/PII:S1570023210004010?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

https://api.elsevier.com/content/article/PII:S1570023210004010?httpAccept=text/plain

17 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences

17 June 2024

published in

1 reference

26 July 2017

volume

878

1 reference

26 July 2017

issue

25

1 reference

26 July 2017

page(s)

2299-2306

1 reference

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis

26 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

17 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

17 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria

17 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

17 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study

17 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.

17 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry

17 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

17 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JCHROMB.2010.06.018

17 June 2024

Identifiers

1 reference

26 July 2017

1 reference